IQVIA (NYSE:IQV) Downgraded by StockNews.com to Hold

IQVIA (NYSE:IQV) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other equities research analysts have also commented on the company. UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Robert W. Baird reduced their target price on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. The Goldman Sachs Group dropped their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $259.13.

IQVIA Trading Down 1.6 %

Shares of NYSE IQV opened at $217.68 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a twelve month low of $190.20 and a twelve month high of $261.73. The company’s fifty day moving average is $232.31 and its 200-day moving average is $229.48. The stock has a market cap of $39.51 billion, a price-to-earnings ratio of 28.57, a P/E/G ratio of 2.15 and a beta of 1.51.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Capital Performance Advisors LLP bought a new position in IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp bought a new stake in IQVIA during the 3rd quarter worth $28,000. Versant Capital Management Inc grew its holdings in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the second quarter valued at $27,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the second quarter worth approximately $29,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.